Studies on antithrombotic effects of recombinant hirudin.
Recombinant desulfato hirudin (rH) was studied with regard to its effects on various models of thrombosis, its pharmacokinetic behaviour as well as its influence on primary haemostasis in rats. The pharmacological behaviour of rH proved to be similar to that of native hirudin. Depending on the different models of experimental thrombosis different dosages of rH were required to prevent thrombus formation. This corresponds to rH plasma concentrations of 0.5-1.5 micrograms/ml. Primary haemostasis is influenced only after excess dosages and plasma concentrations of 4 micrograms/ml and above.
Institute of Pharmacology and Toxicology, Medical Academy Erfurt, GDR.
F
F
Markwardt
B
B
Kaiser
G
G
Nowak
D000818:Animals; D001166:Arteriovenous Shunt, Surgical; D001760:Bleeding Time; D002339:Carotid Arteries; D015951:Factor Xa; D005260:Female; D024764:Hirudin Therapy; D006629:Hirudins / Q000493:pharmacokinetics / Q000494:pharmacology; D006706:Homeostasis / Q000187:drug effects; D007601:Jugular Veins; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D011994:Recombinant Proteins / Q000627:therapeutic use; D012697:Serine Endopeptidases; D013927:Thrombosis / Q000188:drug therapy* / Q000209:etiology
D006629:Hirudins; D011994:Recombinant Proteins; D012697:Serine Endopeptidases; D015951:Factor Xa